Humoral and cellular immune response to AZD1222 /Covishield and BV152/Covaxin COVID-19 vaccines among adults in India
Several COVID-19 vaccines were developed using different approaches to prevent both symptomatic COVID-19 cases and fatalities. The adults were vaccinated with two doses of AZD1222/Covishield (n = 77) [manufactured by Serum Institute of India Pvt Ltd] vaccine and BV152/Covaxin (n = 99) [manufactured...
Saved in:
Main Authors: | Anuradha S. Tripathy (Author), Dharmendra Singh (Author), Diptee Trimbake (Author), Sukeshani Salwe (Author), Srikanth Tripathy (Author), Arjun Kakrani (Author), Priyanka Jali (Author), Hanmant Chavan (Author), Pragya Yadav (Author), Rima Sahay (Author), Prakash Sarje (Author), Prasad Babar (Author), Anita Shete (Author), Ashok Nandapurkar (Author), Milind Kulkarni (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2024-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A study to describe the pattern of cutaneous adverse effects of COVID-19 vaccines (Covishield and Covaxin)
by: Neerja Saraswat, et al.
Published: (2023) -
India's Contribution during COVID-19 Pandemic: COVISHIELD and COVAXIN
by: Kusum K Rohilla, et al.
Published: (2021) -
Effectiveness of the BBV-152 and AZD1222 vaccines among adult patients hospitalized in tertiary hospitals in Odisha with symptomatic respiratory diseases: A test-negative case-control study
by: Debdutta Bhattacharya, et al.
Published: (2023) -
Immunogenicity of SARS-CoV-2 vaccines BBV152 (COVAXIN®) and ChAdOx1 nCoV-19 (COVISHIELD™) in seronegative and seropositive individuals in India: a multicentre, nonrandomised observational studyResearch in context
by: Mangaiarkarasi S. Asokan, et al.
Published: (2024) -
Evaluation of immunogenicity post two doses of inactivated SARS-CoV-2 vaccine, Covaxin after six months
by: Rima R. Sahay, et al.
Published: (2022)